Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.50 |
| ▸ | NOS1 | P29475 | 6/20 | 0.50 |
| ▸ | NOS3 | P29474 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604010 | 1.00 | NOS2 (0.50) | NOS2NOS1NOS3ALDH1A1CYP1A2 | |
| SCHEMBL4632522 | 0.94 | NOS2 (0.44) | NOS2NOS1NOS3ALDH1A1CYP1A2 | |
| SCHEMBL4632518 | 0.94 | NOS2 (0.44) | NOS2NOS1NOS3ALDH1A1CYP1A2 | |
| SCHEMBL3091594 | 0.86 | NOS2 (0.40) | NOS2NOS1NOS3TDP1CYP2C19 | |
| SCHEMBL4603896 | 0.86 | NOS2 (0.40) | NOS2NOS1NOS3TDP1CYP2C19 | |
| SCHEMBL4631200 | 0.83 | NOS2 (0.42) | NOS2NOS1NOS3CYP2C19MEN1 | |
| SCHEMBL1527394 | 0.83 | NOS2 (0.65) | NOS2NOS1NOS3CYP1A2CYP2C19 | |
| SCHEMBL25629375 | 0.83 | NOS2 (0.65) | NOS2NOS1NOS3CYP1A2CYP2C19 | |
| SCHEMBL1527395 | 0.83 | NOS2 (0.65) | NOS2NOS1NOS3CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL8127399 | 0.81 | NOS2 (0.62) | NOS2NOS1NOS3CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016105448-A1 | IMIDAZOLINE RECEPTOR TYPE 1 LIGANDS FOR USE AS THERAPEUTICS | RIDEOUT DARRYL (US) | 2016-06-30 | — | — | WO | disclosed |
| EP-1924568-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1915351-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| WO-2007011623-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011623-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011618-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011618-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | TP53, TP53BP1, ACIN1 | NOS2 2571/4885NOS1 2160/4885NOS3 1034/4885 |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | TP53, ACIN1, TP53BP1 | NOS2 2281/4885NOS1 1779/4885NOS3 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.